We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


01 Mar 2020 - 05 Mar 2020
05 Mar 2020 - 07 Mar 2020
11 Mar 2020 - 13 Mar 2020

Accuracy of Self-Sampling for HPV Screening Evaluated

By LabMedica International staff writers
Posted on 13 Feb 2019
Print article
Image: An Evalyn Brush used for patient self-sampling of the cervico-vaginal area (Photo courtesy of Rovers Medical Devices).
Image: An Evalyn Brush used for patient self-sampling of the cervico-vaginal area (Photo courtesy of Rovers Medical Devices).
Molecular testing for human papillomavirus (HPV) using patient-collected cervico-vaginal samples has shown similar levels of accuracy to testing done on clinician-collected samples and could boost participation in overall HPV screening.

Detecting cancer lesions in women who periodically attend clinics can be more difficult than detecting them in underscreened women who have rarely or never been screened, or have refused to attend clinics following an invitation from a screening organization.

Scientists at the Vrije Universiteit (Amsterdam, the Netherlands) examined 7,643 women aged 29 to 61 years in a self-sampling group and 6,282 in a clinician-collected sampling group. The primary endpoints of the study were detection of cervical intraepithelial neoplasia of grade 2 and worse or grade 3 and worse (CIN2+ or CIN3+). The women were requested to collect their own cervicovaginal sample using an Evalyn Brush; or a clinician-based sampling group, in which samples were collected by a general practitioner with a Cervex-Brush also from Rovers Medical Devices BV.

All samples were tested for HPV using the clinically validated GP5+/6+ PCR enzyme immunoassay. HPV-positive women in both groups were retested with the other collection method and triaged by cytology and repeat cytology in accordance with current Dutch screening guidelines. Of the self-collecting patients, 569, or 7.4%, tested positive for HPV, while in the physician-collected group, 451, or 7.2% tested positive. The CIN2+ sensitivity and specificity of HPV testing did not differ between the two groups, while CIN3+ relative sensitivity was 0.99 with essentially equivalent specificity.

The authors concluded that HPV testing done with a clinically validated PCR-based assay had similar accuracy on self-collected and clinician-collected samples in terms of the detection of CIN2+ or CIN3+ lesions. These findings suggest that HPV self-sampling could be used as a primary. Johannes Berkhof, PhD, a professor and a co-author of the study, said, “"Self-collection has potential to become a first screening test in many different countries. It creates a high participation rate, which is difficult to achieve. We have cleared the first hurdle, but now we need to see how we can implement this kind of screening.” The study was published on January 15, 2019, in the journal Lancet Oncology.

Related Links:
Vrije Universiteit

Print article


Molecular Diagnostics

view channel
Image: Illustration of a 2019- novel coronavirus (nCoV) virion (Photo courtesy of Alissa Eckert, MS/CDC).

The Randox Laboratories Diagnostic Test Distinguishes Coronavirus from Other Respiratory Infections

The global health diagnostics company Randox Laboratories (Crumlin, United Kingdom) has announced the release of a rapid diagnostic test for the COVID-19 strain of coronavirus. A novel coronavirus of... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.